Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605486 · ClinicalTrials.gov registry record · Phase 1
Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
A Phase 1 study of Metastatic Breast Cancer (MBC), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 5
- Study locations
NCT02605486 is a Phase 1 study of Metastatic Breast Cancer (MBC) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT02605486, a Phase 1 study of Metastatic Breast Cancer (MBC), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to test the safety and effectiveness of the investigational drug, palbociclib with bicalutamide for the treatment of triple negative, androgen receptor positive breast cancer.
Conditions Studied
Interventions
- DRUG Palbociclib
- DRUG Bicalutamide
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-11-11 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02605486
The ClinicalTrials.gov registry entry for NCT02605486 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer (MBC) appearing as the primary indexed condition, and to 2 interventions - of which Palbociclib is the first listed.
NCT02605486 reports 5 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02605486 about?
NCT02605486 is a clinical study titled "Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)". The purpose of this study is to test the safety and effectiveness of the investigational drug, palbociclib with bicalutamide for the treatment of triple negative, androgen receptor positive breast cancer.
What is the current status of trial NCT02605486?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2015-11-11. Estimated completion is 2026-11.
What conditions does trial NCT02605486 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer (MBC).
What interventions are being tested in trial NCT02605486?
The interventions under investigation include: Palbociclib (DRUG), Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT02605486?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02605486 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer (MBC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.